Strides board approves USD 15 million investments in Stelis Biopharma

Strides Pharma Science’s board has approved participation in the Series B fundraiser of Stelis Biopharma with a commitment of USD 15 million. The first close of the current fund raise is USD 35 million, of which Strides will commit USD 15 million and USD 20 million is from other existing shareholders. Stelis intends to raise a total of USD 100 million through the fund-raising activity. Strides currently own 36.25 percent stake in Stelis. With the first close of Series B, Stelis would have raised an equity capital of USD 114 million of which Strides would have invested USD 37 million for an effective ownership of 38 percent.